155.68

2.12% -3.37

After Hours: 155.68

Krystal Biotech Inc (KRYS)

Overview News Price History Option Chain Why KRYS Down? Discussions Forecast

Krystal Biotech Inc stock is currently priced at $155.68, with a 24-hour trading volume of 238.31K. It has seen a -2.12% decreased in the last 24 hours and a -8.13% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $160.9 pivot point. If it approaches the $153.0 support level, significant changes may occur.

Previous Close:

$159.05

Open:

$155.61

24h Volume:

238.31K

Market Cap:

$4.40B

Revenue:

Net Income/Loss:

$10.93M

P/E Ratio:

-105.90

EPS:

-1.47

Net Cash Flow:

$-100.60M

1W Performance:

-5.06%

1M Performance:

-8.13%

6M Performance:

+35.48%

1Y Performance:

+78.14%

1D Range:

$153.44

$157.71

52W Range:

$82.09

$189.97

Krystal Biotech Inc Stock (KRYS) Company Profile

Name

Krystal Biotech Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

412-586-5830

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA

Employee

Twitter

@KrystalBiotech

Next Earnings Date

2024-05-17

Latest SEC Filings

KRYS's Discussions on Twitter

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-12-23	Initiated	Citigroup	Buy
Sep-07-23	Initiated	Berenberg	Buy
Apr-18-23	Initiated	Stifel	Buy
Feb-28-23	Upgrade	Goldman	Neutral → Buy
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-18-22	Initiated	BofA Securities	Buy
Jul-20-21	Upgrade	Goldman	Neutral → Buy
Sep-18-20	Initiated	B. Riley FBR	Buy
Jun-04-20	Initiated	Evercore ISI	Outperform
Sep-24-19	Initiated	Goldman	Neutral
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jun-24-19	Reiterated	Chardan Capital Markets	Buy
Jun-24-19	Reiterated	H.C. Wainwright	Buy
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight

View All

Krystal Biotech Inc Stock (KRYS) Latest News

Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround

Zacks Investment Research

Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable

Zacks Investment Research

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

GlobeNewswire Inc.

Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why

Zacks Investment Research

Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks Investment Research

Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?

Zacks Investment Research

Krystal Biotech Inc Stock (KRYS) Financials Data

Krystal Biotech Inc (KRYS) Net Income 2024

KRYS net income (TTM) was $10.93 million for the quarter ending December 31, 2023, a +107.81% increase year-over-year.

Krystal Biotech Inc (KRYS) Cash Flow 2024

KRYS recorded a free cash flow (TTM) of -$100.60 million for the quarter ending December 31, 2023, a +34.48% increase year-over-year.

Krystal Biotech Inc (KRYS) Earnings per Share 2024

KRYS earnings per share (TTM) was $0.09 for the quarter ending December 31, 2023, a +101.63% growth year-over-year.

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is based in Pittsburgh, Pennsylvania.